| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/13/2023 | 225.95% | Truist Securities | $21 → $25 | Maintains | Buy |
| 01/10/2023 | 134.68% | Piper Sandler | $16 → $18 | Maintains | Overweight |
| 11/09/2022 | 160.76% | HC Wainwright & Co. | $30 → $20 | Maintains | Buy |
| 08/23/2022 | 173.79% | Truist Securities | $37 → $21 | Maintains | Buy |
| 05/23/2022 | 82.53% | Piper Sandler | $29 → $14 | Maintains | Overweight |
| 05/11/2022 | 291.13% | HC Wainwright & Co. | $35 → $30 | Maintains | Buy |
| 11/17/2021 | 291.13% | Berenberg | → $30 | Initiates Coverage On | → Buy |
| 06/18/2021 | 356.32% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 12/03/2020 | 225.95% | Stifel | → $25 | Initiates Coverage On | → Buy |
| 09/02/2020 | 173.79% | Jefferies | → $21 | Initiates Coverage On | → Buy |
| 07/16/2020 | 134.68% | Wells Fargo | → $18 | Initiates Coverage On | → Overweight |
| 05/13/2020 | 121.64% | HC Wainwright & Co. | $18 → $17 | Reiterates | → Buy |
| 01/13/2020 | 134.68% | SunTrust Robinson Humphrey | → $18 | Initiates Coverage On | → Buy |
| 10/07/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 09/05/2019 | 108.6% | JMP Securities | → $16 | Reinstates | → Market Outperform |
| 07/18/2019 | 186.83% | Deutsche Bank | → $22 | Initiates Coverage On | → Buy |
| 04/29/2019 | 134.68% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 10/22/2018 | 199.87% | Piper Sandler | → $23 | Initiates Coverage On | → Overweight |
| 10/22/2018 | 265.06% | JMP Securities | → $28 | Initiates Coverage On | → Outperform |
| 10/22/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/22/2018 | 160.76% | Wedbush | → $20 | Initiates Coverage On | → Outperform |
What is the target price for Sutro Biopharma (STRO)?
The latest price target for Sutro Biopharma (NASDAQ: STRO) was reported by Truist Securities on January 13, 2023. The analyst firm set a price target for $25.00 expecting STRO to rise to within 12 months (a possible 225.95% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sutro Biopharma (STRO)?
The latest analyst rating for Sutro Biopharma (NASDAQ: STRO) was provided by Truist Securities, and Sutro Biopharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Sutro Biopharma (STRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on January 13, 2023 so you should expect the next rating to be made available sometime around January 13, 2024.
Is the Analyst Rating Sutro Biopharma (STRO) correct?
While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a maintained with a price target of $21.00 to $25.00. The current price Sutro Biopharma (STRO) is trading at is $7.67, which is out of the analyst's predicted range.